Immunotherapy for melanoma
- 1 May 2004
- journal article
- review article
- Published by Elsevier in Clinics in Dermatology
- Vol. 22 (3) , 251-265
- https://doi.org/10.1016/j.clindermatol.2003.12.001
Abstract
No abstract availableKeywords
This publication has 115 references indexed in Scilit:
- Cancer immunoediting: from immunosurveillance to tumor escapeNature Immunology, 2002
- AUTOCRINE AND PARACRINE REGULATION BY CYTOKINES AND GROWTH FACTORS IN MELANOMACytokine, 2000
- Requirement for Type 2 NO Synthase for IL-12 Signaling in Innate ImmunityScience, 1999
- Loss of HLA class I antigens by melanoma cells: molecular mechanisms, functional significance and clinial relevanceImmunology Today, 1995
- Tumor Rejection After Direct Costimulation of CD8 + T Cells by B7-Transfected Melanoma CellsScience, 1993
- Clinical applications of interleukin-2Progress in Growth Factor Research, 1992
- A Gene Encoding an Antigen Recognized by Cytolytic T Lymphocytes on a Human MelanomaScience, 1991
- Constant-Infusion Recombinant Interleukin-2 in Adoptive Immunotherapy of Advanced CancerNew England Journal of Medicine, 1987
- Observations on the Systemic Administration of Autologous Lymphokine-Activated Killer Cells and Recombinant Interleukin-2 to Patients with Metastatic CancerNew England Journal of Medicine, 1985
- Vitiligo in patients with metastatic melanoma: A good prognostic signJournal of the American Academy of Dermatology, 1983